ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
CT-based renal artery caliber change as a potential imaging marker of treatment response in renal cell carcinoma; an exploratory imaging study.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate whether treatment-induced changes in tumor-bearing renal artery caliber on contrast-enhanced CT are associated with pathological response and pathological downstaging after systemic therapy in locally advanced or metastatic renal cell carcinoma (RCC), and to explore the clinical relevance of this vascular parameter.
methodsWe retrospectively analyzed 43 patients with locally advanced or metastatic RCC who underwent systemic therapy followed by nephrectomy. Renal artery inner diameter was measured on arterial-phase CT before and after treatment using curved planar reformation. Interobserver reproducibility of the measurement was excellent (intraclass correlation coefficient [ICC] = 0.992). A subset of 33 patients had adequate bilateral imaging for tumor-bearing versus contralateral comparison. Tumor size was measured as the longest axial diameter on contrast-enhanced CT, and tumor shrinkage was expressed as percentage change from baseline according to RECIST 1.1 measurement principles. Choi criteria incorporated tumor size and attenuation changes. Pathological response was defined as the proportion of treatment-induced necrosis and fibrosis. Associations between arterial caliber change, pathological response, and pathological downstaging were assessed. Multivariable regression analysis identified independent predictors of pathological response. Discriminative ability for downstaging was evaluated using receiver operating characteristic analysis.
resultsAt baseline, the tumor-bearing renal artery had a larger inner diameter than the contralateral artery. After systemic therapy, its diameter significantly decreased (6.35 to 5.65 mm, p < 0.001). In the paired subset (n = 33), significant reduction occurred only in tumor-bearing arteries. Percentage diameter reduction correlated with pathological response (r = 0.314, p = 0.040). Patients with pathological downstaging showed greater diameter reduction than those without downstaging (16.3% vs 6.83%, p = 0.021). Tumor size change based on RECIST principles and Choi criteria were not significantly associated with downstaging. Multivariable analysis confirmed renal artery diameter change rate as an independent predictor of pathological response. ROC analysis showed moderate discrimination for downstaging (AUC 0.71, 95% CI: 0.55-0.87).
conclusionReduction in tumor-bearing renal artery caliber was independently associated with pathological response and downstaging. This vascular parameter may complement conventional tumor-centered imaging criteria in selected patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.